Thermal stability of vaccines

Authors

  • Duane T. Brandau,

    1. Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047
    Search for more papers by this author
  • Latoya S. Jones,

    1. Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047
    Search for more papers by this author
  • Christopher M. Wiethoff,

    1. Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047
    Search for more papers by this author
  • Jason Rexroad,

    1. Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047
    Search for more papers by this author
  • C. Russell Middaugh

    Corresponding author
    1. Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047
    • Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047. Telephone: 785-864-5813; Fax: 785-864-5814
    Search for more papers by this author

Abstract

Worldwide vaccination programs against infectious diseases and toxins are estimated to save approximately 3 million lives yearly. Tragically, however, another 3 million individuals (primarily children) die of vaccine-preven diseases. A significant portion of this problem results from the thermal instability of many of the currently used vaccines. This review argues that modern methods of physical and chemical analysis permit for the first time characterization of the degradative pathways of thermally labile vaccines. A rigorous description of these pathways permit a more rational and systematic approach to the stabilization of vaccines. A direct result of the replacement of currently employed, primarily empirical, approaches to vaccine stabilization with a more molecular-based methodology should be the development of more universally available vaccinations against life-threatening diseases. This has the potential to have a dramatic impact on world health. © 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 92:218–231, 2003

Ancillary